Imatinib (Addition) -- Adults and Children
Drug information
Section 8: Antineoplastic, immunosuppressives and medicines used in palliative care 8.2: Cytotoxic and adjuvant medicines
Formulation:
Tablet: 100 mg; 400 mg.
Application prepared by:
Union for International Cancer Control, 62 Route de Frontenex, 1207 Geneva, Switzerland and Dana-Farber Cancer Institute, Center for Global Cancer Medicine, Boston, MA 02215, USA
-
Cover letter from the Union for International Cancer Control (UICC)
pdf, 81kb -
Review of the available evidence on Imatinib for Inclusion in the WHO Essential Medicines List as an anti-neoplastic agent
pdf, 593kb - EXPERT REVIEWS
Comments from:
Letters of support from:
-
Children's Oncology Group
pdf, 162kb -
The American Society of Pediatric Hematology Oncology
pdf, 253kb -
International Confederation of Childhood Cancer Parent Organizations (ICCCPO), The Netherlands
pdf, 100kb -
SLACOM, Argentina
pdf, 69kb -
The American Society of Clinical Oncology
pdf, 231kb -
Livestrong, USA
pdf, 33kb -
Partners In Health, Boston, USA
pdf, 218kb -
Ministry of Health, Rwanda
pdf, 2.68Mb -
The European Society for Medical Oncology
pdf, 84kb